AMBLYOTECH
Amblyotech is the developer of novel electronic media therapies designed for the treatment of Amblyopia and other ocular diseases and conditions in adults and children. It has developed a revolutionary treatment to cure Amblyopia without the need of current treatment options, including patching, atropine drops, and surgery The company was founded in 2013 and headquartered in Atlanta, Georgia.
AMBLYOTECH
Industry:
Digital Media Electronics Health Care Medical
Founded:
2013-01-01
Address:
Atlanta, Georgia, United States
Country:
United States
Website Url:
http://www.amblyotech.com
Total Employee:
1+
Status:
Closed
Contact:
(770) 366-6229
Email Addresses:
[email protected]
Total Funding:
602.2 K USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail GStatic Google Static Content Twemoji Akamai DNS
Similar Organizations
Entrada Therapeutics
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
Equinox
Equinox is a developer of a medical technology in revolutionizing the treatment of glaucoma and other progressive eye diseases.
Impact Biomedicines
Impact Biomedicines is pioneering the development of life-changing treatments for patients.
Current Employees Featured
Founder
Official Site Inspections
http://www.amblyotech.com
- Host name: 104.18.11.115
- IP address: 104.18.11.115
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Amblyotech"
Novartis acquires Amblyotech, pursuing novel digital therapy for ...
Designed to enhance compliance, Amblyotech utilizes active gaming and passive video technology with 3-D glasses, training the eyes to work together to view an image in full. Its …See details»
Amblyotech Company Profile - Office Locations, Competitors
Amblyotech is a clinical-stage digital therapeutics company that develops solutions for treating and diagnostics of amblyopia and other ocular disorders. It builds interactive games …See details»
Amblyotech, A Digital Therapeutics Company, Announces It Has …
Apr 20, 2020 Amblyotech is a digital therapeutics company founded by Joseph Koziak (CEO) ... Organization Profile. Amblyotech Inc. Contact Cision. 866-245-2317 from 8 AM - 10 PM ET …See details»
Amblyotech Company Profile 2024: Valuation, Investors
Amblyotech was founded in 2013. Where is Amblyotech headquartered? Amblyotech is headquartered in Phoenix, AZ. What is the size of Amblyotech? Amblyotech has 3 total …See details»
Novartis acquires Amblyotech - 2020-04-20 - Crunchbase
Apr 20, 2020 Amblyotech Amblyotech is the developer of novel electronic media therapies designed for the treatment of Amblyopia and other ocular diseases. Acquiring Organization: …See details»
Novartis acquires Amblyotech, pursuing novel digital
Apr 20, 2020 Peter Zuest Novartis External Communications +41 79 899 9812 (mobile) [email protected] Eric Althoff Novartis US External Communications +1 646 438 4335See details»
Novartis Acquires Lazy Eye Treatment Company …
Amblyotech’s gaming approach uses a visual presentation called dichoptic display, where each eye is presented with different images using an algorithm that encourages the weaker eye to work harder. In early clinical studies, a …See details»
Amblyotech - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Jan 24, 2018: Seed Round - …See details»
Novartis expands ophthalmology pipeline with …
Apr 20, 2020 Novartis Ophthalmology global business franchise head Nikos Tripodis said: “By offering a noninvasive solution that has the potential to be significantly faster than current standards of care such as patching for children …See details»
Novartis buys Amblyotech to develop tech products for lazy eye
Apr 20, 2020 Novartis <NOVN.S> has bought U.S. software start-up Amblyotech, to develop digital technology to treat children and adults with lazy eye, the Swiss drugmaker said …See details»
Novartis Buys U.S. Start-Up Amblyotech For Lazy Eye Treatment
Apr 20, 2020 The Swiss drugmaker said it plans to work together with Ubisoft to develop the Amblyotech software as a medical device, create a series of engaging games for the device, …See details»
Novartis Is Playing Serious Games | by Matteo Fabiano - Medium
Jun 1, 2020 Amblyotech is an Atlanta-based developer of digital therapies for the treatment of amblyopia (a.k.a. lazy eye), a condition that affects about 3% of the population, and other …See details»
Amblyotech, A Digital Therapeutics Company, Announces It Has …
Apr 20, 2020 Amblyotech is a digital therapeutics company founded by Joseph Koziak (CEO) and Robert Derricotte (COO) to develop technologies originally discovered by Dr. Robert Hess.See details»
Novartis acquires digital therapeutic using video games, 3D …
Apr 20, 2020 Amblyotech's approach employs dichoptic display, an approach where each eye is presented with a different algorithm-driven image through the 3D glasses that the brain works …See details»
Amblyotech - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Amblyotech is actively using 8 technologies for its website, according to BuiltWith. These include SPF , Microsoft Exchange Online , and DMARC . Website Tech Stack by BuiltWithSee details»
Ubisoft Entertainment : Novartis acquires Amblyotech, pursuing …
Apr 21, 2020 Basel - Novartis announced today that it has completed the acquisition of Amblyotech, a US-based software startup, and will, in collaboration with Ubisoft and McGill …See details»
Novartis buys Amblyotech to develop tech products for lazy eye
ZURICH, April 20 (Reuters) - Novartis has bought U.S. software start-up Amblyotech, to develop digital technology to treat children and adults with lazy eye, the Swiss drugmaker said on …See details»
Novartis ventures again into digital therapeutics with 'lazy eye' …
Apr 20, 2020 Using 3D glasses and a tablet, Amblyotech’s “Dig Rush” app delivers different images to each eye—in this case, different gameplay elements such as movable, cartoon …See details»